Menu

MorphoSys is dedicated to become a fully integrated biopharmaceutical company. Our business strategy brings more value for patients, investors and partners.

More Info

First MorphoSys-antibody approved
Tremfya® (Guselkumab) now available in US, Europe and Canada!

More Info

We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.

Find out more about our therapeutic pipeline.

More Info

MorphoSys's vision

MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Our focus is on cancer. Innovative technologies and smart development strategies are central to our approach.

learn more about the company

Latest
news

05/02/2019
MorphoSys Announces Appointment of David Trexler as President and Member...
Read Media Release
31/01/2019
MorphoSys Announces Settlement in Patent Lawsuit with Janssen and Genmab
Read Media Release
26/01/2019
Ad hoc: MorphoSys Announces That Its Patents Were Ruled Invalid in Patent...
Read Media Release
17/01/2019
MorphoSys Announces that its Licensee Janssen has Expanded Clinical...
Read Media Release
17/12/2018
MorphoSys AG: Corporate Calendar 2019
Read Media Release
12/12/2018
MorphoSys's Licensee Janssen Announces Data from the Phase 3 Head-to-...
Read Media Release
07/12/2018
Ad hoc: MorphoSys Announces that According to a Presentation Title at an...
Read Media Release
02/12/2018
MorphoSys Presents Updated Data from L-MIND Study of MOR208 plus...
Read Media Release
26/11/2018
MorphoSys Announces Approval of Tremfya(R) (Guselkumab) in Japan for the...
Read Media Release
19/11/2018
MorphoSys Announces Its Licensee Janssen Initiated a Phase 2 Study (NOVA)...
Read Media Release

January 21, 2019
Kepler Chevreux German Corporate Conference
Frankfurt, Germany

See conference

 

 

 

 

Interview with
Simon Moroney, CEO